Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

CEO Tells Scrip Licensing Pact Is Its First, But Not Last

 
• By Sten Stovall
  
Cancer cell
LTX-315 is a first-in-class oncolytic peptide based immunotherapy • Source: Shutterstock

More from Deals

More from Business